Pipeline
Overview
Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases.
Our Licensed Small Molecule Oncology Programs
Our Licensed Small Molecule Autoimmune & Dermatology Programs
Clinical Program
SLX-0528 (previously XT-0528, BOS-172767, ARN-6039)
a clinical stage oral ROR-γt inverse agonist for the treatment of psoriasis and potentially other autoimmune disorders further licensed to Xenter, Inc., in June 2021.
Mechanism of Action: The nuclear hormone receptor retinoic acid-related orphan receptor gamma t (ROR-γt) is a transcription factor (TF) specific to TH17 cells that produce interleukin (IL)-17 and have been implicated in a wide range of autoimmunity.
ARN-3261 (Now called GRN-300)
Inhibitor of SIK2 (Salt Inducible Kinase 2)
Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors was initiated in Q2 2021.
The pipeline above provides the most advanced programs in the areas of Oncology, Autoimmune, CNS/Neurodegenerative diseases and stages of drug development process.
a clinical stage oral ROR-γt inverse agonist for the treatment of psoriasis and potentially other autoimmune disorders further licensed to Xenter, Inc., in June 2021.
Mechanism of Action: The nuclear hormone receptor retinoic acid-related orphan receptor gamma t (ROR-γt) is a transcription factor (TF) specific to TH17 cells that produce interleukin (IL)-17 and have been implicated in a wide range of autoimmunity.
ARN-3261 (Now called GRN-300)
Inhibitor of SIK2 (Salt Inducible Kinase 2)
Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors was initiated in Q2 2021.
The pipeline above provides the most advanced programs in the areas of Oncology, Autoimmune, CNS/Neurodegenerative diseases and stages of drug development process.